Prolonged paralysis after long-term vecuronium infusion

Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 1992-02, Vol.20 (2), p.304-306
Hauptverfasser: VANDERHEYDEN, BETH A, REYNOLDS, H NEAL, GEROLD, KEVIN B, EMANUELE, TULLIO
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 306
container_issue 2
container_start_page 304
container_title Critical care medicine
container_volume 20
creator VANDERHEYDEN, BETH A
REYNOLDS, H NEAL
GEROLD, KEVIN B
EMANUELE, TULLIO
description Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (>3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.
doi_str_mv 10.1097/00003246-199202000-00019
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00003246_199202000_00019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1346591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</originalsourceid><addsrcrecordid>eNp1kctOAyEUhonR1Fp9BJNZuEU5XGbK0jTekia60DU5ZcCOzqWBjk3fXurUupKEwOF8PwkfhGTAroHp4oalIbjMKWjNGU8VTRP0ERmDEqngWhyTMWOaUSG1OCVnMX4kQqpCjMgIhMyVhjEpXkJXd-27K7MVBqy3sYoZ-rUL2e6Ypk2TfTnbh66t-iarWt_HqmvPyYnHOrqL_Tohb_d3r7NHOn9-eJrdzqkVU6kp5xK8lLDgTIKzfoEonSq9Usg8ao6l1QJynArtXF46C3lCFbMgilJ4LSZkOtxrQxdjcN6sQtVg2BpgZqfC_KowBxXmR0WKXg7RVb9oXPkXHN6e-lf7PkaLtQ_Y2ioeMAWaKykSJgds09XJRvys-40LZumwXi_Nfx8hvgH3cXXR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prolonged paralysis after long-term vecuronium infusion</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</creator><creatorcontrib>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</creatorcontrib><description>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (&gt;3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-199202000-00019</identifier><identifier>PMID: 1346591</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: Williams &amp; Wilkins</publisher><subject>Adult ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Humans ; Infusions, Intravenous ; Intensive Care Units ; Male ; Medical sciences ; Paralysis - chemically induced ; Pharmacology. Drug treatments ; Respiration, Artificial ; Time Factors ; Toxicity: nervous system and muscle ; Vecuronium Bromide - administration &amp; dosage ; Vecuronium Bromide - adverse effects</subject><ispartof>Critical care medicine, 1992-02, Vol.20 (2), p.304-306</ispartof><rights>Williams &amp; Wilkins 1992. All Rights Reserved.</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5192543$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1346591$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VANDERHEYDEN, BETH A</creatorcontrib><creatorcontrib>REYNOLDS, H NEAL</creatorcontrib><creatorcontrib>GEROLD, KEVIN B</creatorcontrib><creatorcontrib>EMANUELE, TULLIO</creatorcontrib><title>Prolonged paralysis after long-term vecuronium infusion</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (&gt;3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Intensive Care Units</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Paralysis - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiration, Artificial</subject><subject>Time Factors</subject><subject>Toxicity: nervous system and muscle</subject><subject>Vecuronium Bromide - administration &amp; dosage</subject><subject>Vecuronium Bromide - adverse effects</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOAyEUhonR1Fp9BJNZuEU5XGbK0jTekia60DU5ZcCOzqWBjk3fXurUupKEwOF8PwkfhGTAroHp4oalIbjMKWjNGU8VTRP0ERmDEqngWhyTMWOaUSG1OCVnMX4kQqpCjMgIhMyVhjEpXkJXd-27K7MVBqy3sYoZ-rUL2e6Ypk2TfTnbh66t-iarWt_HqmvPyYnHOrqL_Tohb_d3r7NHOn9-eJrdzqkVU6kp5xK8lLDgTIKzfoEonSq9Usg8ao6l1QJynArtXF46C3lCFbMgilJ4LSZkOtxrQxdjcN6sQtVg2BpgZqfC_KowBxXmR0WKXg7RVb9oXPkXHN6e-lf7PkaLtQ_Y2ioeMAWaKykSJgds09XJRvys-40LZumwXi_Nfx8hvgH3cXXR</recordid><startdate>199202</startdate><enddate>199202</enddate><creator>VANDERHEYDEN, BETH A</creator><creator>REYNOLDS, H NEAL</creator><creator>GEROLD, KEVIN B</creator><creator>EMANUELE, TULLIO</creator><general>Williams &amp; Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199202</creationdate><title>Prolonged paralysis after long-term vecuronium infusion</title><author>VANDERHEYDEN, BETH A ; REYNOLDS, H NEAL ; GEROLD, KEVIN B ; EMANUELE, TULLIO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3849-2241f441b2041ecfbaa4e5df55a0fa92adc9316a839ee6dec16b2050c137d3f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Intensive Care Units</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Paralysis - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiration, Artificial</topic><topic>Time Factors</topic><topic>Toxicity: nervous system and muscle</topic><topic>Vecuronium Bromide - administration &amp; dosage</topic><topic>Vecuronium Bromide - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VANDERHEYDEN, BETH A</creatorcontrib><creatorcontrib>REYNOLDS, H NEAL</creatorcontrib><creatorcontrib>GEROLD, KEVIN B</creatorcontrib><creatorcontrib>EMANUELE, TULLIO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VANDERHEYDEN, BETH A</au><au>REYNOLDS, H NEAL</au><au>GEROLD, KEVIN B</au><au>EMANUELE, TULLIO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prolonged paralysis after long-term vecuronium infusion</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>1992-02</date><risdate>1992</risdate><volume>20</volume><issue>2</issue><spage>304</spage><epage>306</epage><pages>304-306</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>Vecuronium, a nondepolarizing neuromuscular blocking agent, has been used in patients with severe respiratory failure to reduce oxygen consumption and improve total thoracic compliance (1, 2). For short-term administration, vecuronium is regarded as a medication producing therapeutic benefits with few side-effects (3–5). However, the long-term use of vecuronium (&gt;3 days) has been the topic of only two published reports (6, 7).In our ICU, patients initially receive a loading dose of 0.1 mg/kg vecuronium followed by a maintenance infusion of 0.07 to 0.14 mg/kg-hr (8). Some patients exhibit a “resistance” to the agent and require considerably greater hourly doses to permit controlled mechanical ventilation. Nerve stimulators may not be of value to assess degree of paralysis, since the ulnar nerve response to Train-of-Four method does not accurately represent the degree of diaphragmatic paralysis (9). Despite higher than recommended doses and lack of monitoring, most patients regain neuromuscular function within 24 to 48 hrs. Occasionally, however, a patient remains paralyzed for weeks.We describe a patient with severe adult respiratory distress syndrome without renal or hepatic dysfunction, who manifested prolonged paralysis after longterm use of a continuous vecuronium infusion.</abstract><cop>Hagerstown, MD</cop><pub>Williams &amp; Wilkins</pub><pmid>1346591</pmid><doi>10.1097/00003246-199202000-00019</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-3493
ispartof Critical care medicine, 1992-02, Vol.20 (2), p.304-306
issn 0090-3493
1530-0293
language eng
recordid cdi_crossref_primary_10_1097_00003246_199202000_00019
source MEDLINE; Journals@Ovid Complete
subjects Adult
Biological and medical sciences
Drug toxicity and drugs side effects treatment
Humans
Infusions, Intravenous
Intensive Care Units
Male
Medical sciences
Paralysis - chemically induced
Pharmacology. Drug treatments
Respiration, Artificial
Time Factors
Toxicity: nervous system and muscle
Vecuronium Bromide - administration & dosage
Vecuronium Bromide - adverse effects
title Prolonged paralysis after long-term vecuronium infusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T13%3A20%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prolonged%20paralysis%20after%20long-term%20vecuronium%20infusion&rft.jtitle=Critical%20care%20medicine&rft.au=VANDERHEYDEN,%20BETH%20A&rft.date=1992-02&rft.volume=20&rft.issue=2&rft.spage=304&rft.epage=306&rft.pages=304-306&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/00003246-199202000-00019&rft_dat=%3Cpubmed_cross%3E1346591%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1346591&rfr_iscdi=true